Davis KA, Nanga RP, Das S, Chen SH, Hadar PN, Pollard JR, et al
de FigueiredoSMBindaNSNogueira-MachadoJAVieira-FilhoSACaligiorneRB
(2022) demonstrated Cerebrolysin's effects on Alzheimer's disease biomarkers in a randomized controlled trial, providing objective biological evidence for its neurotrophic activity (PMID: 36155516) Regulatory Validation: Approved for clinical use in over 40 countries for indications including stroke, traumatic brain injury, and dementia (though not FDA-approved in the United States) Dihexa: Preclinical Only, with Integrity Concerns Dihexa's evidence base is entirely preclinical and has faced significant scientific integrity challenges: Foundational Research: Wright et al
Effect of obesity on neonatal outcomes in pregnancies with preterm premature rupture of membranes
The Sonora substellar atmosphere models
While the process can be uncomfortable, both laser and saline removal methods are designed to minimize pain